Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 2,374 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Visual Function Clear all
Completed Phase 2 Interventional

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

NCT00287521
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
AL-37807 Ophthalmic Suspension, 1.0%, Latanoprost, 0.005% (Xalatan), AL-37807 Vehicle, Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 22, 2026, 11:18 PM EDT
Terminated Not applicable Interventional

Ocular Comfort and Inflammation in Lid Hygiene Therapy

NCT02938078
View directory record Official record
Conditions
Blepharitis
Interventions
Avenova Lid Cleanser
Device
Lead sponsor
Minnesota Eye Consultants, P.A.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bloomington, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 22, 2026, 11:18 PM EDT
Terminated Phase 2 Interventional

The Effectiveness of Ologen® Collagen Matrix in Preventing Intraocular Pressure (IOP) Spikes After Ahmed Glaucoma Valve Surgery (AGV-FP7)

NCT02990143
View directory record Official record
Conditions
Glaucoma
Interventions
Ologen
Procedure
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 22, 2026, 11:18 PM EDT
Completed Phase 3 Interventional Results available

Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection

NCT00440947
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions
Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r), Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
62
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2012 · Synced Oct 22, 2026, 11:18 PM EDT
Terminated Phase 4 Interventional Results available

Effect of Topical Botulinum Toxin Eyedrop on Palpebral Fissure

NCT06080438
View directory record Official record
Conditions
Tears; Excess, Eyelid Spasm
Interventions
Botulinum toxin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 22, 2026, 11:18 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

NCT00572455
View directory record Official record
Conditions
Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions
PF-04217329 - Lowest Dose, PF-04217329 - Low Dose, PF-04217329 - Middle Dose, PF-04217329 - High Middle Dose, PF-04217329 - High Dose, PF-4217329 - Highest Dose, PF-04217329 - Vehicle, Latanoprost Vehicle, Latanoprost 0.005%
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
23
States / cities
Artesia, California • Newport Beach, California • Petaluma, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 22, 2026, 11:18 PM EDT
Terminated Phase 3 Interventional Results available

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery

NCT01298752
View directory record Official record
Conditions
Inflammation, Pain, Cataract
Interventions
Mapracorat, Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 22, 2026, 11:18 PM EDT
Completed Early Phase 1 Interventional

Effect of Nutritional Supplement Alpha-ketoglutarate for Age-related Ocular Disease

NCT07269704
View directory record Official record
Conditions
Eye Diseases
Interventions
Calcium alpha-ketoglutarate
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 22, 2026, 11:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers

NCT00608699
View directory record Official record
Conditions
Healthy Subjects, Dyslipidaemias
Interventions
GSK256073A tablets + IR niacin tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Oct 22, 2026, 11:18 PM EDT
Completed Phase 2 Interventional Results available

Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye

NCT01393132
View directory record Official record
Conditions
Dry Eye, Sjogren's Syndrome, Graft vs. Host Disease
Interventions
Thymosin Beta 4 eye drops, Vehicle Control
Drug
Lead sponsor
Michigan Cornea Consultants, PC
Other
Eligibility
18 Years to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 22, 2026, 11:18 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation

NCT04234932
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
Netarsudil Ophthalmic
Drug
Lead sponsor
University of the Incarnate Word
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Oct 22, 2026, 11:18 PM EDT
Not listed No phase listed Observational

Glaucoma HFA / OCT Specificity Study

NCT02708082
View directory record Official record
Conditions
Glaucoma
Interventions
OCT scanning and HFA perimetry
Device
Lead sponsor
Carl Zeiss Meditec, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Dublin, California
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Oct 22, 2026, 11:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Universal Eye Drop Adherence Monitor to Measure and Improve Adherence to Ocular Medications

NCT03506568
View directory record Official record
Conditions
Medication Adherence, Glaucoma
Interventions
Devers Drop Device (D3) app
Device
Lead sponsor
Universal Adherence LLC
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 22, 2026, 11:18 PM EDT
Not listed Not applicable Interventional

Use of Nanodropper vs. Standard Eyedropper in Patients With Glaucoma and Ocular Hypertension

NCT05277870
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Nanodropper adaptor, control
Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 22, 2026, 11:18 PM EDT
Recruiting Phase 3 Interventional

A Randomized Trial to Evaluate Sequential vs Simultaneous Patching

NCT04378790
View directory record Official record
Conditions
Amblyopia
Interventions
Patching, Glasses
Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
3 Years to 13 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
68
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 22, 2026, 11:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

KETODEX for Emergence Delirium in Children Undergoing Outpatient Strabismus Surgery

NCT03779282
View directory record Official record
Conditions
Emergence Delirium, Strabismus
Interventions
Dexmedetomidine
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
Up to 18 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Jefferson, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 22, 2026, 11:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Characterizing the Intraocular Scattering at Different Wavelengths

NCT05602623
View directory record Official record
Conditions
Vision, Ocular
Interventions
Adaptive Optics System (AO)
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 22, 2026, 11:18 PM EDT
Not listed Phase 2 Interventional

Rho Kinase (ROCK) Inhibitor in Tauopathies - 1

NCT04734379
View directory record Official record
Conditions
Progressive Supranuclear Palsy, Corticobasal Syndrome
Interventions
Fasudil
Drug
Lead sponsor
Woolsey Pharmaceuticals
Industry
Eligibility
35 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2022 · Synced Oct 22, 2026, 11:18 PM EDT
Not listed Not applicable Interventional

Study of an Intervention to Improve Problem List Accuracy and Use

NCT01105923
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Asthma, COPD, Breast Cancer, Coronary Artery Disease, Congestive Heart Failure, Diabetes, Glaucoma, Hemophilia, Hypertension, Hyperthyroidism, Hypothyroidism, Myasthenia Gravis, Osteoporosis, Osteopenia, Renal Failure, Renal Insufficiency, Sickle Cell Disease, Stroke
Interventions
MAPLE
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Oct 22, 2026, 11:18 PM EDT
Active, not recruiting Not applicable Interventional

Binocular iPad Sub-Study

NCT02365090
View directory record Official record
Conditions
Amblyopia
Interventions
patching, binocular games
Other
Lead sponsor
Retina Foundation of the Southwest
Other
Eligibility
4 Years to 14 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 22, 2026, 11:18 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Objective Evaluation of Ocular Surface Lubricants in Two Environments

NCT01375582
View directory record Official record
Conditions
Dry Eye
Interventions
B & L Soothe Lubricant Eye Drops, Liposic EDO, OcuFresh Eye Wash
Drug
Lead sponsor
University of Rochester
Other
Eligibility
30 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 22, 2026, 11:18 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis

NCT04485546
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
cenegermin-bkbj
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
San Diego, California • Edgewood, Kentucky • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 22, 2026, 11:18 PM EDT
Terminated Phase 2 Interventional

Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis

NCT03536559
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis, Optic Neuropathy, Optic; Neuritis, With Demyelination
Interventions
CNM-Au8, Placebo
Drug
Lead sponsor
Clene Nanomedicine
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 22, 2026, 11:18 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients Wtih Glaucoma or Ocular Hypertension

NCT00332072
View directory record Official record
Conditions
Ocular Hypertension
Interventions
bimatoprost/timolol fixed combination
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Ogden, Utah
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 22, 2026, 11:18 PM EDT